Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat's Effects on Reverse Remodeling Indices in HFrEF
NCT07405944Phase 4Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Vericiguat oral suspension (Formulation 4) in heart failure with reduced ejection fraction (HFrEF), sponsored by University Medical Centre Ljubljana. Started Nov 2025; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07405944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405944.